Use of prescription opioid and other drugs among a cohort of persons with Ehlers–Danlos syndrome

A retrospective study

Jane R. Schubart, Amber Schilling, Eric Schaefer, Rebecca Bascom, Clair Francomano

Research output: Contribution to journalArticle

Abstract

Against the backdrop of increased opioid prescribing in the United States and the associated high rate of side effects, dependence, and addiction, our study examined how opioids and other medications are being used among persons with Ehlers–Danlos syndrome (EDS). EDS is a set of heritable connective tissue disorders with high symptom burden, including chronic pain. Prescription medication use among persons with EDS was compared to a cohort of matched controls using 10 years of administrative claims data from a large database of privately insured patients (2005–2014). Our dataset included 4,294 persons with EDS, ages 5–62 years old. In both adults and children, we found that the percentage of persons with a prescription drug claim was higher in the EDS cohort for all prescription drug classes examined. Among children, opioid use was double in the EDS cohort compared to the control group (27.5% vs. 13.5%); in adults, it was nearly double in EDS patients (62% vs. 34.1%). Among persons who were prescribed opioids, those with EDS had higher cumulative dosages over a 2-year time period versus controls. Our study aids in understanding opioid and prescription drug use patterns in a vulnerable population with high symptom burden and chronic pain that is often severe.

Original languageEnglish (US)
Pages (from-to)397-403
Number of pages7
JournalAmerican Journal of Medical Genetics, Part A
Volume179
Issue number3
DOIs
StatePublished - Mar 1 2019

Fingerprint

Opioid Analgesics
Prescriptions
Retrospective Studies
Pharmaceutical Preparations
Prescription Drugs
Chronic Pain
Vulnerable Populations
Connective Tissue
Databases
Control Groups

All Science Journal Classification (ASJC) codes

  • Genetics
  • Genetics(clinical)

Cite this

@article{61274a8e627f40079dc22c0e4591a07f,
title = "Use of prescription opioid and other drugs among a cohort of persons with Ehlers–Danlos syndrome: A retrospective study",
abstract = "Against the backdrop of increased opioid prescribing in the United States and the associated high rate of side effects, dependence, and addiction, our study examined how opioids and other medications are being used among persons with Ehlers–Danlos syndrome (EDS). EDS is a set of heritable connective tissue disorders with high symptom burden, including chronic pain. Prescription medication use among persons with EDS was compared to a cohort of matched controls using 10 years of administrative claims data from a large database of privately insured patients (2005–2014). Our dataset included 4,294 persons with EDS, ages 5–62 years old. In both adults and children, we found that the percentage of persons with a prescription drug claim was higher in the EDS cohort for all prescription drug classes examined. Among children, opioid use was double in the EDS cohort compared to the control group (27.5{\%} vs. 13.5{\%}); in adults, it was nearly double in EDS patients (62{\%} vs. 34.1{\%}). Among persons who were prescribed opioids, those with EDS had higher cumulative dosages over a 2-year time period versus controls. Our study aids in understanding opioid and prescription drug use patterns in a vulnerable population with high symptom burden and chronic pain that is often severe.",
author = "Schubart, {Jane R.} and Amber Schilling and Eric Schaefer and Rebecca Bascom and Clair Francomano",
year = "2019",
month = "3",
day = "1",
doi = "10.1002/ajmg.a.61031",
language = "English (US)",
volume = "179",
pages = "397--403",
journal = "American Journal of Medical Genetics, Part A",
issn = "1552-4825",
publisher = "Wiley-Liss Inc.",
number = "3",

}

Use of prescription opioid and other drugs among a cohort of persons with Ehlers–Danlos syndrome : A retrospective study. / Schubart, Jane R.; Schilling, Amber; Schaefer, Eric; Bascom, Rebecca; Francomano, Clair.

In: American Journal of Medical Genetics, Part A, Vol. 179, No. 3, 01.03.2019, p. 397-403.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Use of prescription opioid and other drugs among a cohort of persons with Ehlers–Danlos syndrome

T2 - A retrospective study

AU - Schubart, Jane R.

AU - Schilling, Amber

AU - Schaefer, Eric

AU - Bascom, Rebecca

AU - Francomano, Clair

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Against the backdrop of increased opioid prescribing in the United States and the associated high rate of side effects, dependence, and addiction, our study examined how opioids and other medications are being used among persons with Ehlers–Danlos syndrome (EDS). EDS is a set of heritable connective tissue disorders with high symptom burden, including chronic pain. Prescription medication use among persons with EDS was compared to a cohort of matched controls using 10 years of administrative claims data from a large database of privately insured patients (2005–2014). Our dataset included 4,294 persons with EDS, ages 5–62 years old. In both adults and children, we found that the percentage of persons with a prescription drug claim was higher in the EDS cohort for all prescription drug classes examined. Among children, opioid use was double in the EDS cohort compared to the control group (27.5% vs. 13.5%); in adults, it was nearly double in EDS patients (62% vs. 34.1%). Among persons who were prescribed opioids, those with EDS had higher cumulative dosages over a 2-year time period versus controls. Our study aids in understanding opioid and prescription drug use patterns in a vulnerable population with high symptom burden and chronic pain that is often severe.

AB - Against the backdrop of increased opioid prescribing in the United States and the associated high rate of side effects, dependence, and addiction, our study examined how opioids and other medications are being used among persons with Ehlers–Danlos syndrome (EDS). EDS is a set of heritable connective tissue disorders with high symptom burden, including chronic pain. Prescription medication use among persons with EDS was compared to a cohort of matched controls using 10 years of administrative claims data from a large database of privately insured patients (2005–2014). Our dataset included 4,294 persons with EDS, ages 5–62 years old. In both adults and children, we found that the percentage of persons with a prescription drug claim was higher in the EDS cohort for all prescription drug classes examined. Among children, opioid use was double in the EDS cohort compared to the control group (27.5% vs. 13.5%); in adults, it was nearly double in EDS patients (62% vs. 34.1%). Among persons who were prescribed opioids, those with EDS had higher cumulative dosages over a 2-year time period versus controls. Our study aids in understanding opioid and prescription drug use patterns in a vulnerable population with high symptom burden and chronic pain that is often severe.

UR - http://www.scopus.com/inward/record.url?scp=85059691061&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059691061&partnerID=8YFLogxK

U2 - 10.1002/ajmg.a.61031

DO - 10.1002/ajmg.a.61031

M3 - Article

VL - 179

SP - 397

EP - 403

JO - American Journal of Medical Genetics, Part A

JF - American Journal of Medical Genetics, Part A

SN - 1552-4825

IS - 3

ER -